Author:
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 408 | 95 | 8 |
| Full Text Views | 5 | 0 | 0 |
| PDF Downloads | 3 | 0 | 0 |
Serum Sickness with Furazolidone
Martin S. Wolfe
Martin S. Wolfe
Office of Medical Services, Department of State, American Embassy, Washington, D.C. 20520, Panama
Search for other papers by Martin S. Wolfe in
Current site
Google Scholar
PubMed
Search for other papers by Martin S. Wolfe in
Current site
Google Scholar
PubMed
Austin L. Moede
Austin L. Moede
Office of Medical Services, Department of State, American Embassy, Washington, D.C. 20520, Panama
Search for other papers by Austin L. Moede in
Current site
Google Scholar
PubMed
Search for other papers by Austin L. Moede in
Current site
Google Scholar
PubMed
Two cases of serum sickness from furazolidone (Furoxona®), prescribed for giardiasis in Latin America, are described. No previous case of serum sickness related to this drug has been reported in the United States. Tartrazine (yellow dye number 5), a component of furazolidone tablets (Furoxona) manufactured in Latin American countries but no longer included in the drug (Furoxone®) in the United States is suggested as a possible cause of serum sickness.
Author Notes
Presently Regional Medical Officer, American Embassy, Athens, Greece.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 408 | 95 | 8 |
| Full Text Views | 5 | 0 | 0 |
| PDF Downloads | 3 | 0 | 0 |